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Galectins are a phylogenetically conserved family of soluble β-galactoside binding
proteins, consisting of 15 different types, each with a specific function. Galectins
contribute to placentation by regulating trophoblast development, migration, and
invasion during early pregnancy. In addition, galectins are critical players regulating
maternal immune tolerance to the embedded embryo. Recently, the role of galectins
in angiogenesis during decidualization and in placenta formation has gained attention.
Altered expression of galectins is associated with abnormal pregnancies and infertility.
This review focuses on the role of galectins in pregnancy-associated processes and
discusses the relevance of galectin-glycan interactions as potential therapeutic targets
in pregnancy disorders.
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INTRODUCTION
During pregnancy, a delicately regulated interplay of endocrine, immune andmetabolic processes is
established in order to sustain offspring development. The coordination of a series of simultaneous
events occurring at both sides of the maternal-fetal interface, including multiple signaling
pathways driving cell growth and differentiation, vascular development, and immune regulation,
is critical for a successful pregnancy outcome. At the maternal site, complex immunoregulatory
mechanisms support active tolerance of fetal alloantigens while also remaining competent to
elicit an effective response toward pathogenic insults (1). Throughout pregnancy the uterine
vascular bed experiences dramatical changes with extensive remodeling of existing vessels and
formation of new networks through the process of angiogenesis (2), allowing for the proper
delivery of oxygen and nutrients to the developing fetus. In parallel, at the fetal site, the process of
placentation relies on a complex interaction between invasive trophoblasts and maternal immune
cells involving developmentally regulated periods of branching angiogenesis, non-branching
angiogenesis, trophoblast differentiation and syncytium formation. Disruption of this normal
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pattern of placental development will directly impact placental
function, with well-recognized consequences leading to
suboptimal pregnancy outcomes (3).
The placenta sustains pregnancy by providing an
immunological barrier between the mother and fetus, mediating
the transfer of gases, nutrients and water and secreting a variety
of hormones, cytokines, and signaling factors. As the active
interface mediating maternal-fetal communication, the placenta
plays a key role in sensing and modulating perturbations in
the maternal environment and transmitting these stimuli to
the developing fetus, with potential consequences in long-term
offspring health. Indeed, it is now well-recognized than an
adverse intrauterine environment during early development
can modify disease predisposition in adult life as stated in
the so-called “developmental origins of health and disease”
or “fetal programming” paradigm. From the time of pioneer
studies correlating birth weight and altered fetal growth
with predisposition to chronic conditions as cardiovascular
disease and diabetes (4), accumulating experimental evidence
has contributed to the identification of multiple maternal
constitutional and life style factors that can impact long-
term individual health as well as the mechanisms involved
in the transmission of these programming stimuli across the
placenta (5–7).
Among the multiple mediators involved in pregnancy
orchestration, the galectin family of β-galactoside binding
proteins elicits great interest in the reproductive medicine field
due to their unique ability to modulate diverse developmental
processes and their potential use as biomarkers for gestational
disorders. In this review we discuss the current knowledge on the
role of galectins in supporting maternal adaptations to pregnancy
and placental development, the impact of their dysregulation
for development of disease and the potential application of
galectinome profiling studies for diagnostic and therapeutic
interventions in adverse pregnancy outcomes.
GENERAL ASPECTS OF GALECTINS
Complex carbohydrates on the cell surface and the extracellular
matrix (ECM) encode abundant structural information that
when decoded by specific carbohydrate-binding proteins
(lectins) modulates interactions between cells, or cells and
the ECM (8, 9). Based on their structural folds and canonical
sequence motifs in the carbohydrate recognition domain (CRD),
lectins have been organized into several families that include
galectins (formerly S-type lectins), C-type, F-type, X-type,
R-type, P-type, and several other families [Reviewed in (10)].
The taxonomic distribution of selected lectin families and
their structural analysis have yielded critical information about
their functional aspects and evolutionary history. While F- and
C-type lectins—are largely heterogeneous and evolutionary
diversified lectin families (11, 12), from a structural standpoint,
galectins are relatively conserved (13, 14). Galectins are non-
glycosylated soluble proteins characterized by a unique sequence
motif in their CRDs and affinity for β-galactosides (13). Most
galectins show preference for N-acetylated disaccharides such
as N-acetyl-lactosamine (LacNAc; Galβ1,4GlcNAc) and related
structures, whereas others have preference for blood group
oligosaccharides (13–15).
Galectins are synthesized in the cytoplasm, and can be
translocated into the nucleus where they can form part of
the spliceosome (16, 17). Galectins can also be secreted to
the extracellular space by non-classical mechanisms as they
lack a typical signal peptide possibly by direct transport across
the plasma membrane (18). Once secreted, galectins bind
to carbohydrate ligands in the ECM and the cell surface,
namely glycans that display LacNAc and polylactosamine chains
[(Galβ1, 4GlcNAc)n] (13) (Figure 1). These include laminin and
fibronectin, mucins, lysosome-associated membrane proteins,
and numerous cell surface glycoproteins (19–22). Among
the latter, galectins bind with high affinity to glycosylated
cell surface signaling molecules such as α and β integrins
(21) and the signaling mucin MUC1 (22). Integrins are
the predominant laminin and fibronectin-binding proteins
expressed on differentiating cells and represent important
ligands for galectins involved in cell adhesion, motility and
differentiation (21–24). For some galectins, the immediate
binding to ligands in the oxidative extracellular environment
is key to the stability of their carbohydrate-binding activity
(25). The crystal structure of galectin-1 (Lgals1) revealed six
key cysteine residues, some of which are located on the surface
of the molecule on the face opposite to the CRD and are
potentially susceptible to oxidation (26–28). Under non-reducing
conditions, intramolecular disulfide bridges are formed resulting
in conformational changes that preclude Lgals1 from forming
a dimer (29). A critical interplay takes place between the
oxidation state of cysteine sulfhydryl groups and the ligand
binding and dimerization equilibrium, suggesting that specific
binding to glycan ligands enhances dimerization and reduces
sensitivity to oxidative inactivation (25). In addition, extracellular
galectins can also recognize exogenous ligands, such as glycans
on the surface of viruses, bacterial pathogens and parasites (30–
33), a hallmark of other lectin types, such as C-type lectins
(11). Furthermore, galectin secretion into the extracellular space
upon stress has been proposed to constitute non-infectious
“danger signals” that can initiate or exacerbate inflammatory
responses (34).
STRUCTURAL ASPECTS OF GALECTINS
Galectins are characterized by their extensive taxonomic
distribution and striking evolutionary conservation of primary
structures, gene organization, and structural fold (11). The
identification of galectin-like proteins in the fungus Coprinopsis
cinerea (35) and in the sponge Geodia cydonium (36) revealed
structural conservation of galectins in eukaryotic evolution.
Furthermore, proteins sharing the galectin structural fold
identified in the protozoan parasite Toxoplasma gondii (37, 38)
and in rotaviruses (39–41) suggest either early emergence of the
galectin fold or horizontal transfer from the vertebrate hosts,
respectively. In general, galectin polypeptide subunits exhibit a
relatively simple domain organization, housing one, two, or four
galectin CRDs (11).
Although galectins have been evolutionarily conserved (42),
the galectin repertoire in any given mammalian species is
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FIGURE 1 | Summary of galectins’ glycan specificity, functions and sources of expression in mammalian pregnancies. Question marks (?) denote putative functions
(not yet experimentally confirmed in the context of pregnancy). BG, blood group; uNK, uterine natural killer; ICM, inner cell mass; VT, villous cytotrophoblast; EVT,
extravillous trophoblast; Syn, syncytiotrophoblast; GDM, gestational diabetes mellitus; SA, spontaneous abortion; PE, preeclampsia; HELLP, hemolysis elevated liver
enzymes and low platelet syndrome; GTD, gestational trophoblastic disease; IUGR, intrauterine growth restriction. ↑ and ↓ denote increased/peak and decreased
expression, respectively. Mannose Galactose N-acetylglucosamine N-acetylgalactosamine Sialic Acid Fucose.
constituted by multiple galectin types, subtypes, and isoforms
(13). Based on the CRD organization of the polypeptide
monomer, mammalian galectins (and by extension, galectins
in all vertebrate taxa) have been classified in three major
types: “proto,” “chimera,” and “tandem-repeat” (TR) types (43)
(Figure 1). Proto-type galectins contain one CRD per subunit
and can form concentration-dependent non-covalently linked
homodimers. Dimerization of proto-type galectins is key to their
function in mediating cell-cell or cell-ECM interactions (44, 45).
Two Lgals1 monomers interact via amino acid residues from a
hydrophobic core that establish a dimerization equilibrium with
a Kd of 7µM (16). Both proto- and TR-type galectins comprise
several distinct subtypes, all numbered in the order of their
discovery, while chimera galectins include a single subtype (13).
Lgals1,−2,−5,−7,−10,−11,−13,−14, and−15, are included in
the proto-type. Chimera-type galectins, represented by Lgals3,
have a C-terminal CRD and a proline- and glycine-rich N-
terminal “tail.” Ligand-driven interactions of Lgals3 subunits
via the N-terminal domain mediate their oligomerization into
trimers and pentamers (46). TR galectins display two similar—
albeit not identical—CRDs connected by a functional linker
peptide (47), and comprise the Lgals4, −6, −8, −9, and
−12 subtypes. Galectin subtypes may be expressed as multiple
isoforms in a single cell type or as tissue-specific variants
generated by alternative splicing (13, 48), positive selection, and
amino acid replacements in carbohydrate-recognition domains
(49). Among the proto, chimera and TR galectin types, several
subtypes, that include human Lgals1, Lgals2, Lgals3, Lgals9,
and three galectins that cluster in the human chromosome 19
[Lgals13 (pp. 13),−14, and−16], have been recently investigated
with regards to their potential roles in fertilization, embryo
implantation, placentation, and the various stages of normal and
pathological pregnancy (49–52).
The structural fold of Lgals1 and the amino acid residues
of the CRD that directly or indirectly—via water molecules—
interact with the hydroxyl groups on the carbohydrate ligands
have been identified by the resolution of the crystal structure
of the Lgals1/LacNAc complex (26, 27, 53). The Lgals1
subunit is a β-sandwich consisting of a 135 amino acid-
long polypeptide that folds into two antiparallel β-sheets of
five and six strands each (S1–S6 and F1–F5). This globular
structure contains one carbohydrate binding cleft formed
by three continuous concave strands (S4–S6) that includes
all amino acid residues that interact with LacNAc and are
responsible for the carbohydrate specificity of Lgals1: histidine
44, asparagine 46, arginine 48, histidine 52, asparagine 61,
tryptophan 68, glutamic acid 71, and arginine 73 (27).
Tryptophan 68 establishes a hydrophobic stacking interaction
with the non-reducing terminal galactose ring. Additional
water-mediated interactions between His52, Asp54, and Arg73
in the Lgals1 CRD with the nitrogen of the NAc group
rationalize the higher affinity for LacNAc over lactose. The
rigorous assessment of the galectins’ carbohydrate-binding
affinity has been enabled by biophysical approaches, such as
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microcalorimetry measurements and surface plasmon resonance
analysis. For example, the dissociation constants of bovine
Lgals1 for Lac, LacNAc, and thiodigalactoside measured by
microcalorimetry were in the range of 10−5 M, with two
binding sites per Lgals1 dimer (54). The overall structure of
the Lgals3 CRD is very similar to the Lgals1 CRD although in
the former the carbohydrate-binding site is shaped as a cleft
open at both ends, exposing the GlcNAc of the LacNAc to
the solvent (55). This extended binding site in Lgals3 results
in increased affinity for polylactosamines and for ABH blood
group oligosaccharides [Fucα1, 2; GalNAcα1,3(Fucα1,2); and
Galα1,3(Fucα1,2)] (55). The structures of the individual N-
and C-terminal CRDs of TR galectins, such as galectins-4,- 8,
and−9, have been resolved by either crystallization or NMR
spectroscopy. Results have shown that the two CRDs in the
same galectin molecule are structurally similar but exhibit either
different affinities for the same ligand such as observed in Lgals4,
or different fold and specificities altogether, such as reported for
Lgals8 (56–58).
Based on analysis of the galectin primary structure and intron-
exon position in various vertebrate species it has been proposed
that along the vertebrate lineages leading to mammals, galectins
evolved by duplication of a primordial single CRD galectin gene
that produced a bi-CRD gene, with the N- and C-terminal CRDs
later diverging into two subtypes (F4-CRD and F3-CRD) of
distinct exon-intron organization. Single-CRD galectins display
the F3- (e.g., Lgals1, −2, −3, −5) or F4- (e.g., Lgals7, −10,
−13, −14) subtypes, while TR galectins display both F4 and F3
subtypes (Lgals4, −6, −8, −9, and −12) (13, 42). In invertebrate
species, galectins exhibit one, two, or four tandem-arrayed CRDs
(59–61). In those invertebrate galectins that carry multiple CRDs,
these are structurally similar but not identical, suggesting that
they differ in their fine carbohydrate specificity (61). How the
multiple CRD galectins from invertebrates relate to the vertebrate
TR galectins remains to be fully understood, but a preliminary
phylogenetic analysis revealed that individual CRDs of a four-
CRD galectin clusters with the mammalian single CRD galectins
rather with the TR galectins, suggesting that this gene is the
product of two consecutive duplications of a single-CRD galectin
gene (61).
FUNCTIONAL ASPECTS OF GALECTINS
As discussed above, TR galectins display two CRDs in a
single polypeptide, that can interact with and cross-link
multivalent ligands, either soluble glycoproteins or glycolipids,
or ECM and complex glycans on the cell surface. Although
proto- and chimera-type galectin subunits possess a single
CRD, they can organize as oligomeric structures that also
bind multivalent ligands with increased avidity (44, 45). The
density of the cell surface glycans and their scaffolding (as
glycoproteins, glycolipids or polysaccharides) modulates affinity
of the CRD-ligand interaction via negative co-operativity
(45), and can lead to ligand cross-linking, and formation of
lattices that cluster these ligands into lipid raft microdomains
(44). These interactions can promote reorganization or
association of cell surface components, regulate turnover of
endocytic receptors, activate or attenuate signaling pathways,
and in turn, modulate cell function (44). Further, because
galectin types and subtypes exhibit notable differences in
carbohydrate specificity and affinity and bind a broad range
of glycans that display the requisite topologies, the galectin
repertoire displays considerable diversity in recognition
properties that together with their distinct and unique tissue
distribution and local concentrations, supports extensive
functional diversification (13, 30). Thus, the biological function
of a particular galectin may vary among cells, tissues and
fluids, depending on their concentration, the availability and
multivalent presentation of suitable carbohydrate ligands, and
the redox properties of any particular intra- or extracellular
microenvironment (30).
EARLY DEVELOPMENT AND
TISSUE REGENERATION
The initial description in the early “80s of developmentally-
regulated galectins in chicken muscle suggested that their
biological roles were related to embryogenesis and early
development. Further, the finding that chicken galectins
preferentially recognized the abundant polylactosamines present
on the myoblast surface and the ECM, suggested that galectins
mediate myoblast fusion [reviewed in (14)]. Later studies
suggested roles of murine Lgals1 and Lgals3 in notochord
development and somitogenesis, and in skeletal muscle and
central nervous system development (62, 63). In recent years,
the increasing availability of null mice for selected galectins
enabled their developmental phenotypic analysis. Although the
phenotypes identified have been in some cases rather subtle,
which hindered a rigorous assignment of the galectins” biological
roles, the use of galectin deficient models and tissue-specific
knockouts is one of the most complete available tools for
the analysis of the biological role of galectins. In addition,
rodents express a complex galectin repertoire; this was attributed
to functional redundancy of the multiple galectin types and
subtypes. However, as the binding properties and natural
ligands of each galectin have been rigorously characterized
in recent years, it has become clear that this is not the
case, and their unique biological roles are being elucidated
in increasing detail. In the past few years, Drosophila, C.
elegans, and zebrafish (Danio rerio) have become useful model
systems to address the biological roles of galectins (64–68).
For example, antisense knockdown approaches in zebrafish
embryos for a Lgals1 isoform (Drgal1-L2) revealed a key role
in differentiation and development of the myotome (69). The
zebrafish model was also useful to assess the roles of galectins
in tissue repair and regeneration (53, 70). Experimentally light-
induced retinal injury in adult zebrafish was used in combination
with an antisense knockdown approach to demonstrate that
photoreceptor cell death upregulates expression and secretion
of DrGal1-L2 by stem cells and neuronal progenitors in the
Müller glia, and selectively regulates the regeneration of rod
photoreceptors (70).
Frontiers in Immunology | www.frontiersin.org 4 May 2019 | Volume 10 | Article 1166
Blois et al. Galectins in Pregnancy
GENOME ORGANIZATION OF GALECTIN
FAMILY MEMBERS
While galectins are usually grouped based on their architecture,
a potential relationship between gene location and function has
been investigated (42, 50). Genes encoding Lgals1 and Lgals2,
named LGALS in humans and Lgals in mice and other chordates,
map to syntenic regions of chromosome 22 and chromosome
15, in humans and mice, respectively. Studies of the promoter
sequences and expression of murine Lgals1, -2 and -7 revealed
significant differences in the proximal promoter regions for
putative transcription factor binding sites in these genes, which
is believed to correlate with the ubiquitous gene expression of
Lgals1 and a more restricted expression of Lgals2 and Lgals7 (71).
Members of the human galectin gene family are found in
different chromosomes, including chromosome 1, 11, 14, 17, 19,
and 22. Than et al. proposed that some of the human galectin
genes clustered in chromosome 19 and expressed in villous
trophoblasts, including LGALS13, LGALS14, LGALS16, are
developmentally regulated by DNA methylation and induced by
transcription factors that drive villous trophoblast differentiation
and trophoblast-specific gene expression (49). In addition,
dysregulation of these galectin genes with a potential role in
immune tolerance to the semi-allogeneic fetus was proposed to
be associated with preeclampsia (49).
Interestingly, the Lgals3 gene is different from other galectin
genes in which gene duplication and inversion within a cluster
has been reported. A single member has been identified per
species hinting at a conserved function of Lgals3 during evolution
(42). In addition, LGALS3 contains an internal gene, which is
much less abundant than LGALS3 transcripts and is expressed
mostly in peripheral blood leukocytes producing an entirely
distinct protein from Lgals3 (72).
ROLE OF GALECTINS IN PREGNANCY
ASSOCIATED PROCESSES
Expression profiling studies in reproductive tissues have shed
important insights on the biological roles played by galectins
in pregnancy orchestration, highlighting the importance of a
delicate interplay between maternal and fetal sources of galectin
expression for healthy outcomes (Figure 1). The following
section provides a brief overview of the role of individual
galectins expressed at the maternal-fetal interface in the
establishment and maintenance of pregnancy.
GALECTIN-1 (LGALS1)
The functions of Lgals1 in the context of pregnancy are the best
characterized when compared to other members of the galectin
family (Figure 1), likely due to its high level of expression by
decidual stromal cells and trophoblast cell populations which
suggested an important function (73). Indeed, Lgals1 has been
shown to play a role in a variety of biological processes highly
relevant for pregnancy orchestration including angiogenesis,
immune response regulation, cell adhesion, invasion, and
cell cycle progression through intracellular or extracellular
mechanisms (23, 74–76).
Lgals1 expression is observed in 3–5 days human embryos
potentially increasing trophoblast attachment to the uterine
epithelium (77). After embryo attachment as the trophoblast
layer differentiates, Lgals1 localizes to villous cytotrophoblast
where it may play a role in promoting syncytium formation,
although this function has only been studied in vitro using the
BeWo trophoblast tumor cell line (78, 79). More recently, Lgals1
has been demonstrated to drive the differentiation of mouse
trophoblast stem (TS) cells in vitro, by enhancing cell migration
and invasiveness associated with a shift in the expression
of matrix metalloproteinases, epithelial-mesenchymal transition
markers and the TGF-β signaling pathway (80). Circulating levels
of Lgals1 increase significantly during pregnancy and several
studies indicate the potential use of Lgals1 as a biomarker
for miscarriage, recurrent fetal loss and preeclampsia (PE)
(77, 81–84). Whether circulating Lgals1 retains carbohydrate-
binding activity within the oxidative nature of the extracellular
environment remains unknown as Lgals1 exhibits exquisite
sensitivity to oxidative inactivation (25, 85). In addition, a further
question regarding concentration of galectins in serum or plasma
is whether high picomolar concentrations are sufficient for
galectins to act at a distance similar to circulating hormones (86).
In this regard, some galectin-mediated cellular activities (e.g.,
Lgals3 and Lgals7) (87, 88) might be sufficiently sensitive to be
elicited by serum levels of galectins.
Lgals1 is highly expressed in the most invasive trophoblast
cells of the placenta and membrane bound Lgals1 has been
proposed to regulate migration of primary trophoblasts and
of an extravillous trophoblast (EVT) cell line (77, 89–91).
Modulation of EVT migration by Lgals1 could be related to its
interaction with the β1 integrin chain on the EVT membrane
(90, 92–94, 94). Another reported ligand for Lgals1 on the EVT
membrane is the mucin MUC1 (95). Expression of MUC1 is
increased during placental development and was found to be
elevated in severe pre-eclamptic placentas (96) although the
significance of this finding is unclear as MUC1 has been shown
to have adhesive and anti-adhesive properties (97). Interestingly,
adhesion and invasion of the HTR-8 SV/neo EVT cell line to
ECM components is negatively affected byMUC1 overexpression
(98). In endothelial cells, the membrane protein neuropilin-
1 was identified as a ligand for Lgals1 and the expression
of neuropilin-1 in decidual cells, intermediate trophoblasts,
and syncytiotrophoblasts has been recently reported (99, 100).
The potential interaction of Lgals1 with neuropilin-1 in these
placental cells could potentially have functional consequences
for placentation. As stated above, besides interacting with
glycoproteins on the cell membrane, Lgals1 interacts with
glycoproteins deposited in the ECM and has been shown to
have both anti-adhesive as well as pro-adhesive extracellular
functions (23). In the placental ECM, Lgals1 ligands include
fibronectin, laminin, and osteopontin, which are also integrin
ligands (19, 101–104).
The importance of Lgals1 as a contributor to feto-maternal
tolerance has been described by many investigators and has been
extensively reviewed (51). Several immune cells with essential
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roles in the establishment and maintenance of pregnancy
synthesize and respond to Lgals1, e.g., CD4+ CD25+ regulatory
T-cells, which play a very important role in tolerating the
immunogenic paternal alloantigens (83, 105–110). In addition,
in vitro studies showed that Lgals1 regulates the expression of
human leucocyte antigen (HLA-G) in EVTs demonstrating that
Lgals1 contributes to tolerance via its interaction with immune
and trophoblast cells (77).
GALECTIN-2 (LGALS2)
Lgals2 is predominantly expressed in the gastrointestinal tract
and has been identified as one of the main gastric mucosal
proteins proposed to have a protective role in the stomach by
interacting with mucins (111). In addition, immune functions
of Lgals2 have been proposed including its ability to induce
apoptosis in activated CD8+ T-cells and its effects on monocytes
(112, 113). Lgals2 was shown to polarize monocytes and
macrophages to a pro-inflammatory, non-arteriogenic M1
phenotype, and reduce monocyte motility. Interestingly, Lgals2
regulation of monocyte/macrophage phenotype were attributed
to its interaction with the lipopolysaccharide-binding protein
CD14 in a non-carbohydrate dependent manner (112, 113).
Lgals2 expression in the placenta was reported in both VT and
EVT cells and was shown to be expressed at higher levels in VT
and EVT of male compared to female placentas. Interestingly,
in cases of intrauterine growth restriction (IUGR), there was no
change in expression in female placentas compared to controls;
however, expression of Lgals2 in male IUGR placentas was
reported to be decreased compared to controls (114). While these
studies should be repeated with a larger sample number, theymay
serve to caution investigators for the need to take the gender of
the fetus into account as an important variable when analyzing
possible changes in galectin expression when comparing normal
to pathologic pregnancies. In addition, Lgals2 expression was
decreased in third-trimester EVT trophoblast cells in cases of PE
on the protein andmRNA level (115) and also significantly down-
regulated in the VT and EVT trophoblast of spontaneous and
recurrent abortion placentas (116).
GALECTIN-3 (LGALS3)
Lgals3 has been implicated in the regulation of innate and
adaptive immune responses, where it participates in the
activation or differentiation of immune cells and contributes
to phagocytic clearance of microorganisms and apoptotic cells
by macrophages (117, 118). Lgals3 has been reported to
promote but also to inhibit T-cell apoptosis depending on
whether it binds to glycoproteins on the cell surface (CD45
and CD71) or to intracellular ligands (Bcl-2) (119, 120). In
the placenta, Lgals3 was detected in all trophoblastic lineages
including villous cytotrophoblasts (CTB) and EVT with a
reduction of Lgals3 expression observed from the VT to
the trophoblastic cell columns (121). This pattern of Lgals3
expression correlates with the switch from a proliferative
to a migratory trophoblast phenotype and while placental
Lgals3 dysregulation has been associated with some obstetric
complications including spontaneous or recurrent miscarriages,
further studies are needed to understand its contribution to
trophoblast biology (81, 122). In addition to trophoblasts, Lgals3
is expressed by maternal decidual cells (73). While showing a
different expression pattern, both Lgals1 and Lgals3 have been
proposed to play a role in cell-cell and cell-matrix interactions of
trophoblast during placentation (121). Studies of the importance
of Lgals3 in murine pregnancy by Yang et al. indicate that
Lgals3 is expressed in the luminal and glandular epithelium
and that an increase in Lgals3 is required for proper embryo
implantation (123). In addition, Lgals3 affects chemotaxis and
morphology of endothelial cells and stimulates capillary tube
formation and angiogenesis in vivo (124). Therefore, besides its
proposed roles in embryo implantation, immune regulation and
trophoblast-matrix interactions, Lgals3 has a potential role in
placental angiogenesis. It must be noted, however, that despite
considerable research efforts over the past years, the precise
physiological relevance of this lectin during pregnancy remains
ill-defined. Comprehensive analysis of the placental phenotype,
the regulation of vascular development and maternal adaptations
in Lgals3 deficient models could greatly aid our understanding of
this lectin’s role in pregnancy orchestration.
GALECTIN-7 (LGALS7)
Lgals7 is produced by the premenstrual and menstrual
endometrial luminal and glandular epithelium, where it
accumulates in menstrual fluid and has been proposed to act as
a paracrine factor to facilitate post-menstrual endometrial re-
epithelialization (125). While Lgals7 mRNA was not detected in
term placenta by real time-PCR, using immunohistochemistry,
expression of Lgals7 was reported in the syncytiotrophoblast
(STB), EVT and glandular epithelium in first trimester placenta,
decidua and in the STB and endothelial cells of normal term
placenta (50, 126). Menkhorst et al. suggested that Lgals7 may
facilitate adhesion of the embryo to the endometrium and
reported that the serum concentration of Lgals7 was significantly
elevated in women (weeks 10–12 and 17–20) who subsequently
developed PE compared to women with healthy pregnancies
(126, 127). Another study, also explored the potential value
of Lgals7 measurement as a biomarker and indicated that
maternal serum Lgals7 levels had no value to predict the risk of
spontaneous abortion (128). Clearly, further studies are required
to confirm the expression of Lgals7 in placental cells and the
potential usefulness of Lgals7 measurements in maternal serum
as a biomarker for pregnancy pathologies should be evaluated
with larger patient cohorts.
GALECTIN-8 (LGALS8)
Lgals8 is ubiquitously expressed and analysis of its expression in
normal first trimester placentas indicated that Lgals8 is expressed
by VT and EVT, and is highly expressed in decidual stromal
cells (129). Lgals8 has been referred to as an “angiogenesis
regulator” in vascular and lymphatic endothelium by binding to
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podoplanin in lymphatic vessels and CD166 (ALCAM, activated
leukocyte cell adhesion molecule) in vascular endothelial cells
(130). The role of this galectin in placental angiogenesis has not
been explored but an initial report indicates that Lgals8 is not
expressed in the endothelium of the placenta (130). The human
gene (LGALS8) encodes seven different isoforms resulting from
alternative splicing but the functional consequences of Lgals8
splicing are poorly understood (130). Pro-inflammatory and
immunosuppressive functions have been both attributed to this
galectin in different experimental systems but so far, no studies
on its possible role as an immunomodulator during pregnancy
have been reported (131–135). Potentially, Lgals8 could play a
role in trophoblast cell adhesion and migration as was reported
in other cell types, but experimental evidence for the regulation
of trophoblast function by this lectin is also lacking (136).
GALECTIN-9 (LGALS9)
The tandem-repeat Lgals9 has been implicated in immune
regulation through binding to TIM-3, CD44 and the cell surface
protein disulfide isomerase (PDI) (137–139). This galectin is
expressed by many cell types including epithelial cells of
the endometrium, trophoblasts, stromal cells of the decidua,
endothelial cells including those in the placenta, and several types
of immune cells (140–143). Splice variants of Lgals9 have been
reported with six of them expressed in human decidua, which
may differ in their biological functions (143–145).
Compared to non-pregnant individuals, regulatory T cells
show higher level of Lgals9 expression as pregnancy proceeds
and the level of Lgals9 in serum is significantly higher in women
with normal pregnancies compared to post-partum and non-
pregnant female controls (146). Interestingly, the serum levels
of Lgals9 in pregnancy varied with the gender of the fetus as
was also reported for some inflammatory cytokines and pro-
angiogenic factors; Lgals9 is further increased in the serum of
women carrying a male compared to a female fetus (147, 148).
Li et al. proposed that Lgals9 contributes to the generation of
CD25+ FoxP3+ T regulatory cells in -circulation and in the
spleen and that engagement of Tim-3 by Lgals9 in peripheral
NK cells facilitates the immunosuppressive activity of these cells
during the first trimester of pregnancy (149). Additionally, they
report that the concentration of Lgals9 in the plasma of women
with normal pregnancies is significantly higher from that in
women suffering from recurrent miscarriages but caution should
be taken as the sample size was small and fetal gender was not
considered in these studies (149).
Recently, lower levels of Lgals9 expression analyzed by
immunohistochemistry were described in trophoblasts of the
DBA/2-mated CBA/J mouse model of spontaneous abortion/PE
when compared to normal CBA/J × BALB/c matings, further
showing that Lgals9 blockade promoted a significant imbalance
of Th1/Th2 immunity in this model (150). Additionally, altered
placental Lgals9 expression together with dysregulated Tim-3
signaling in distinct NK and T cell subsets have been suggested
to mediate the abortifacient effects of mifepristone in mouse
pregnancies (151). Furthermore, activation of Tim-3/Lgals9
signaling pathway promotes decidual macrophages polarization
to M2 subtype, alleviating the PE-like syndrome induced by
LPS in a rat model (152). In conclusion, while a role for
Lgals9 in immune tolerance during pregnancy has been reported
by a handful of investigators, more studies considering splice
variants, fetal gender, and Lgals9 receptors on target cells are
required to better understand the potential role for this galectin
as a contributor of the systemic and local immune regulation
during pregnancy.
GALECTIN-10 (LGALS10)
Prototype Lgals10, also known as eosinophil Charcot-Leyden
crystal protein, appears to play an important role in the
differentiation of neutrophils and the functional properties of
CD25+Treg cells (153, 154). Subsequently, expression of this
lectin at the maternal-fetal interface has been described mainly
in the STB and to a smaller extent in the decidua during
the first trimester, showing decreased levels in spontaneous
abortion patients (116, 155). The precise physiological role played
by this lectin in pregnancy is still unknown but interestingly,
its expression is driven from a chromosome 19 gene cluster
comprising also galectins −13, −14, −16, and −17, which
emerged during primate evolution as a result of duplication and
rearrangement of genes via a birth-and-death process (49, 50).
Galectins in the chromosome 19 cluster show primarily placental
expression and may be involved in the regulation of unique
pregnancy associated processes, including maternal immune
tolerance and villous trophoblast differentiation (49, 50, 156).
GALECTIN 13 (LGALS13)
Lgals13 is also known as placental protein 13 (PP13) and
was first isolated from human placenta (157). This galectin
is predominantly expressed by STB cells of the placenta, in
which nuclear staining and strong labeling of the brush border
membrane is observed (158, 159). Although originally reported
to be absent in serum of pregnant women, Lgals13 is detected
in increasing concentration in maternal serum as pregnancy
progresses becoming undetectable 2–5 weeks post-partum (158,
160, 161). Besides being found in a soluble form in circulation,
Lgals13 is also located inside and on all types of STB-derived
extracellular vesicles (162).
Lgals13 has been proposed to have immune regulatory
functions, and in studies in rodents it has been shown to
reduce blood pressure associated with activation of endothelial
prostaglandin and nitric oxide signaling pathways (163–166).
The potential for Lgals13 as a useful biomarker for PE has been
suggested by Burger and co-workers. They reported that in the
1st trimester, lower than normal Lgals13 levels were found in
IUGR and PE, particularly in the early-onset form. In the 2nd and
3rd trimesters, higher than normal concentrations were found in
PE, IUGR and in preterm delivery (PTD) (160). On the other
hand, lower placental Lgals13 mRNA and protein expression
were found in preterm PE and HELLP syndrome, although
the immunoreactivity of the STB microvillous membrane was
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reported to be stronger in these pregnancies than in age-matched
controls suggesting increased membrane shedding (167). The
usefulness of Lgals13 as a biomarker for PE has been questioned
as late second-trimester Lgals13 alone does not increase the
ability to predict PEwhen compared to second-trimester Doppler
pulsatility index and other potential biochemical markers (168),
highlighting the need to consider the interactions between
different signaling pathways in disease pathogenesis when in
search for sensitive, reliable biomarkers. In this regard, recent
studies suggest that the kinetics of Lgals13 expression in PE
would result from the concerted actions of this protein and
antiangiogenic factors as sFlt-1 on the maternal vascular system,
with a dual role for Lgals13: first in low levels acting as a
priming insult promoting endothelial activation and angiogenic
imbalance, and increasing later in the third trimester as a
natural rescue response promoting maternal vasodilation to
lower blood pressure (169). In the context of gestational diabetes
mellitus (GDM), increased Lgals13 serum levels during the early
second trimester and lower expression in trophoblast cells of
the term placenta have been reported (170, 171). Dysregulation
of Lgals13 was suggested to contribute to an imbalance in
inflammatory processes in the placenta during pregnancy and
therefore possibly lead to GDM.
Interestingly, while Lgals13 has hemagglutination activity
when tested with chicken erythrocytes, a recent report suggested
that contrary to what was observed for other galectins, Lgals13
may not bind carbohydrates (172). Prior studies, however, had
reported that not only the binding of Lgals13 to erythrocytes
or T cells is carbohydrate-dependent (50, 173), but also that
N-acetyllactosamine is the preferred disaccharide ligand for
Lgals13 (50, 159). This inconsistency in the results from the
aforementioned laboratories may reside in that Su et al. (172)
had tested lactose as an inhibitor for Lgals13, as well as other
carbohydrates, such as xylose and arabinose, that are unrelated
to the structures recognized by most galectins. Nevertheless, the
identification of natural ligand(s) for Lgals13 at the cell surface
and extracellular matrix will be of great importance to better
understand its role(s) during pregnancy (165).
GALECTIN-GLYCAN INTERACTIONS AS
REGULATORS OF THE
FETAL-MATERNAL DIALOGUE
Glycosylation is the most common and structurally diverse
type of post-translational modification, affecting proteins, lipids
and the extracellular matrix. Glycans play fundamental roles
in most biological processes, thus it is not surprising that
glycans are profusely expressed in the mammalian uterus
(174). During implantation, the uterine epithelium and the
outer trophoblast cell layer of the implanting embryo interact
in a glyco-specific manner, such that perturbations of the
system generally result in failure of implantation or poor
placentation and compromised pregnancy outcomes. Glycans
are essential functional groups that facilitate and influence the
reproduction process. The synthesis of glycans relies on specific
modification enzymes (glycosyltransferases and glycosidases)
(Figure 2), and the glycocode expressed in a particular tissue
is highly dependent on the cell type and its developmental,
nutritional, and pathological state. The glycans within the
glycome can have multiple functions during pregnancy. For
example, N-linked glycans (attached to the nitrogen of an
asparagine side-chain) play an important role in trophoblast
cell invasion in early pregnancy (175, 176) and maternal-
fetal tolerance (177, 178). O-Linked glycans (attached to the
hydroxyl oxygen of serine, threonine, tyrosine, hydroxylysine
or hydroxyproline side-chains) can influence recognition events
during fertilization (e.g., sperm-egg interactions) (179). As a
detailed discussion about the role of glycosylation—in pregnancy
outcome is beyond the scope of this review, we will focus on
modifications that affect binding and function of members of the
galectin family during gestation.
Extracellularly galectins act by cross-linking N- and O-
glycans on the surface glycoproteins of maternal immune
cells, trophoblasts and endothelial cells at the fetal-maternal
interface. As glycosylation often represent highly regulated post-
translational modifications related to the physiological cellular
status, alterations in glycan composition can fundamentally
impact galectin activity (180–182). Given the prominent
expression of galectins (e.g., Lgals1 and Lgals3) at the fetal-
maternal interface, studies designed to examine the relevance of
cell surface glycans on maternal/ placental compartments are of
key importance. In a physiological context, enhanced expression
of N-acetylglucosaminyl transferase V [GnTV, encoded by the
Mgat5 gene (Figure 2)] was found in placentas from the first
trimester compared with those from full-term pregnancies (175).
GnTV generates β1-6-N-acetylglucosamine branches in complex
N-glycans which are recognized by Lgals1. LacNAc motives
are a glycan signature of EVT (91, 183) as their presence was
detected not only on their surface but also on their secretion
product HLA-G (91, 184). Since Lgals1 promotes trophoblast
invasion and EVT differentiation during early pregnancy (90),
it is possible that the increased activity of GnTV results in
enhanced Lgals1 signaling (176); particularly, by promoting
the interaction of Lgals1 with β1 integrin at the trophoblast
cell membrane (94, 176, 185–190) (Figure 3). Furthermore,
the presence of (β-6) branches and the expression of the
glycosyltransferase GnTV involved in the generation of these
glycan structures were reduced in villous tissues from early
spontaneous miscarriages in comparison with healthy pregnancy
villous tissues (191). Thus, differences in the glycan composition
of trophoblast related-proteins at the same gestational age could
be important disease biomarkers that should be further explored
with newly available mass spectroscopy techniques. Indeed, the
expression of GnTV was reported to be elevated in PE placentas
compared to normal placentas (192). We have shown that Lgals1
expression is increased in late onset PE and could represent a
compensatory mechanism of the trophoblast to overcome the
severe inflammation microenvironment that characterizes PE
disease (74) (Figure 3). This is an interesting link to themetabolic
status of trophoblast cells, which is mediated by the intracellular
levels of GnTV that affect quality and branching of complex
N-glycans and therefore regulate galectin binding.
During pregnancy the STB layer of the placenta releases
extracellular vesicles (STBEV) containing a complex cargo of
RNAs, proteins, lipids, and also glycans into the maternal
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FIGURE 2 | Simplified schematic representation of N-and O-glycan biosynthesis focusing on galectin-1 binding affinity. N-glycans are attached to asparagine (Asn)
residues, whereas O-glycans are attached to either serine (Ser) or threonine (Thr) residues. Gal-1 recognizes galactose on complex N-glycans and sialylation on the
terminal galactose in the α2,6-linkage, but not in the α2,3-linkage, prevents the binding of gal-l. Regarding O-glycans, gal-1 binds to the N-acetyllactosamine
(LacNAc) motif in core 2 O-glycans. ST6GAL-1, β-galactoside α2,6-sialyltransferase 1; MGATS, α1,6-mannosylglycoprotein 6β-N-acetylglucosaminyltransferase;
C2GnT, core 2 β1,6 N-acetylglucosaminyltransferase.
FIGURE 3 | Galectin-1-Giycan axis in the control of pregnancy protective programs. Galectin-1 regulates key process during the course of normal gestation including
trophoblast invasion, maternal immune regulation, and angiogenesis. Relevant examples are illustrated. During Preeclampsia an aberrant α2-6 sialylation decorates
α5β1integrin on the cell surface of EVT trophoblast, cell surface of STVEV released from the STB trophoblast and on endothelial cells. The high expression of α2-6
sialylated N-glycans impairs gal-1-mediated trophoblast ETV cell migration process interfering with the binding to the ECM and subsequently invasion. High α2-6
sialylation on STBEV and impaired gal-l binding might contribute to the pro-inflammatory milieu in maternal circulation and endothelial dysfunction. On vascular
endothelial cells, the aberrant α2-6 sialylation may disrupt gal-1-mediated angiogenesis and early vascularization promoting the anti-angiogenesis status typical of the
syndrome.
circulation potentially to induce maternal immune adaption.
Under pathological conditions such as preeclampsia, however,
STBEV exhibit a differential glycan composition compared to
uneventful pregnancies. In particular, STBEV derived from
PE placentas depict an increased content α2-6-linked sialic
acid (193). The presence of α2-6-linked sialic acid on cell
surface glycoproteins—is mainly determined—by the activity
of the sialyltransferase gene ST6GAL1 and results in blocking
of Lgals1 signaling (194, 195). The selective glycosyltransferase
expression (e.g., ST6Gal-1) on trophoblast cells may be an
early pathological mechanism of masking Lgals1 activity in
modulating the maternal immune response to the developing
embryo. Moreover, an increased α2-6 sialylation was observed
on the STB layer and also in placenta vessels derived from
pregnancies complicated with hypertensive disorders including
superimposed PE, PE, and PE + HELLP (196). This is
important since high α2-6 sialylation on endothelial cells can
reduce Lgals1 mediated angiogenesis (195), which is in line
with our in vivo experiment showing that blocking Lgals1
mediated angiogenesis with anginex during early gestation in
mice induced spontaneously PE development (74) (Figure 3).
Moreover, the inhibition of Lgals1 binding by sialylation at the
position 6 of galactose has been suggested to make Th1 cells
resistant to apoptosis (197) and might contribute to uncontrolled
maternal inflammation during preeclampsia. Thus, analysis of
the glycosylation signature of trophoblast and placental vessels
constitute a valuable approach to unravel the importance of
galectin signaling through VEGFR2 during gestation.
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CONCLUSIONS AND
FUTURE DIRECTIONS
There is ample evidence showing that galectins are expressed
widely at the feto-maternal interface. Their expression is
regulated during pregnancy and galectins are highly specific
to certain trophoblast and maternal cell types. Multiple
galectin functions have been described in the orchestration of
healthy pregnancy, which include maternal immune adaptation,
placental development, and angiogenesis. Studies on the
association of pregnancy pathologies with dysregulated galectin
expression are still at an early stage, with most of our
knowledge on the biological role of galectins in pregnancy being
inferred from in vitromodels and clinical correlations. However,
sufficient evidence is already available to suggest galectins,
especially Lgals1 and Lgals13, are promising candidates for
further investigation aimed at understanding the pathogenesis
of pregnancy complications including life threatening pregnancy
related diseases such as PE. Because galectins are unique proteins
with ability to recognize and decode a complex array of glycan
motifs, future research could include: (1) a systemic study of
the trophoblast cell-type glycome and galectin expression at
the maternal-fetal interface in health and disease to determine
whether glycomodifications on trophoblast cells that prevent
galectin binding are responsible for the development of some
pregnancy disorders and what is the galectin distribution in the
maternal and placental compartments in health and disease; (2)
a comprehensive analysis of the role of galectins in maternal
circulation during pregnancy to establish whether galectins act at
distance and if the presence of galectins in maternal circulation is
a consequence of leakage from placenta tissue; (3) a deep analysis
of galectin-glycan interactions either at the maternal or placental
compartments with the goal to reveal the critical contribution
of the physiological and pathophysiological galectin functions
during gestation. In the years ahead, the development of novel in
vivo strategies to test hypotheses related to the biology of galectin-
glycan interactions during pregnancy represents a worthwhile
pursuit, which will greatly advance reproductive medicine
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